Soterix touts transcranial stim depression trial results
Soterix Medical today released results from trials of its direct current stimulation-limited total energy technology designed to treat depression, touting that the device was found to be safe and effective with improvements in depression-rating metrics lasting for a month after treatment. The tDCS-LTE system is designed to deliver energy to the dorsolateral prefrontal cortex region of the brain which is implicated in depression control, the New York-based company said. In the first trial, the company reported that its tDCS-LTE system was effective and safe as an add-on intervention for patients with type I or II bipolar disorder during major depressive episodes who are being treated with pharmaceuticals. Data from the 59-patient trial indicated that treatment with the system resulted in a 14-point improvement in the Hamilton Depression Rating scale after 12 treatments, with benefits persisting for over a month. Side effects were found to be no different from placebo, the company added. Results from the first trial were published in the journal JAMA Psychiatry. In the second trial, which enrolled 245 patients, researchers reported that treatment with the tDCS-LTE was superior to placebo, resulting in an 8 point improvement on the HDR scale after 15 weekday treatments followed by seven tapered weekly treatments. Patients treated with the tDCS-LTE group reported higher rates of itching, tingling, tinnitus and nervousness than other groups, while groups receiving only escitalopra...
Conclusions: RDLs are frequently observed in high-risk patients for gastric cancer after eradication. M-NBI demonstrated significantly superior diagnostic efficacy with respect to RDL.Digestion 2018;98:48 –55
Conclusions: The sustained effort to self-manage chronic pain could be exhausting, and motivation could wane over time following intervention. Providing intermittent support in the form of booster sessions and peer support groups may be important. Person-centered care via shared decision making and guided problem solving is essential to facilitating ongoing self-management. PMID: 29669089 [PubMed - in process]
Alopecia areata (AA) is a common autoimmune condition of the skin that causes hair loss from the scalp and body. Recent studies have proposed a relationship between AA and comorbid psychiatric conditions including anxiety and depression. Our aim was to explore the association between depression and AA prospectively. A cohort of 56,079 female nurses from Nurses Health Study (NHS) were followed up from 2002 to 2012 to investigate whether a previous diagnosis of depression (n=36,083) was associated with the risk of self-reported new-onset AA (n=130).
Atopic dermatitis (AD) has been associated with multiple comorbid diseases. However, the relationship between AD severity and disease comorbidities is complex. A cross-sectional US population-based study of 8,217 adult was performed using a structured questionnaire. A diagnosis of AD was determined using UK Diagnostic Criteria for AD (n=602). AD severity was assessed using PO-SCORAD, POEM, DLQI and self-reported global AD severity. Logistic regression and structural equation models (SEM) were used to explore associations of AD with allergic, cardiometabolic, anxiety/depression and autoimmune disease.
The association of mood disorders such as depression and anxiety with chronic pruritus is established.Additionally, certain characteristics such as gender have been shown to increase the risk of concomitant mood disorder symptoms. However, the relationship between quality of life and mood disorder symptoms in patients with chronic pruritus is unknown. We performed a retrospective chart review of patients with chronic pruritus (defined as itch lasting>6 weeks)to assess both patient-reported mood disorder symptoms and quality of life using the Hospital Anxiety and Depression Scale and the Skindex-16, respectively.
The objective of this cross-sectional study was to define the prevalence and impact on Health-Related Quality of Life (HRQoL) of AD in US adults. Disease severity was categorized as clear/mild, moderate or severe based on the Patient Oriented Eczema Measure (POEM). The impact of AD on HRQoL was assessed using Dermatology Life Quality Index (DLQI) and depression and anxiety using the Hospital Anxiety and Depression scale (HADS).
Older adults may be at increased risk for adverse drug events because of comorbid conditions, polypharmacy and altered pharmacokinetics. First generation antihistamines are highly anticholinergic, and put older adults at greater risk of confusion, dry mouth, constipation and other adverse events. Therefore, these medications are listed in the Beers Criteria with a strong ‘avoid’ recommendation. The goal of the study was to examine how often dermatologists prescribe these medications in older adults.
BACKGROUND: Despite high survival rates of non-melanoma skin cancer (NMSC), many patients report unmet supportive care needs, increased cancer-specific and general distress, and higher levels of anxious and depressive symptoms. Virtual reality (VR) has experienced tremendous growth in recent years with rapidly expanding applications. Proof of concept using VR to mitigate stressful healthcare experiences has already been demonstrated in various settings.OBJECTIVE: To assess the utility of a VR experience in the context of the Mohs surgical day as a means to ameliorate patient anxiety and pain.
Acne vulgaris is one of the most common dermatologic disorders and may result in profound negative physical and psychosocial side effects including scarring, low self-esteem, depression and suicidal ideation. This intervention aimed to improve child and adolescent acne care given by primary care pediatricians through intensive education of clinicians and implementation of an electronic medical record (EMR) tool. Pediatricians associated with a tertiary-care children ’s hospital healthcare system in San Diego (n=116) underwent intensive, case-based education on acne assessment and treatment based on published acne treatment guidelines.
The objective of this study was to investigate coping strategies used by patients with HS and the associations of the strategies with HRQOL. A cross-sectional survey was issued to patients with HS at four different sites. The survey included a demographics and disease activity scale, the Brief COPE, the Hospital Anxiety and Depression Scale (HADS), and the Dermatology Life Quality Index (DLQI).